Slide 1: Q1'2022 Results
We engineer enzymes to improve health… of people and the planet Q1’2022 Results May 5, 2022
Slide 2: Forward Looking Statements
Forward Looking Statements • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and
Slide 3: Strengthening Fundamentals Driving Impressive Results
Strengthening Fundamentals Driving Impressive Results Annual Product Revenues Strong Q1’22 Results Up Nearly 4x in Two Years1 140 120 $112M to $118M 100 80 $71M $mm Total revenue growth of 96% YOY 60 40 $30M 20 Quarterly product revenue >3X YOY - FY20 FY21 FY22E Product Revenue Product gross margin
Slide 4: Sustainable Manufacturing: Solid, Growing Base & Continued Execution
Sustainable Manufacturing: Solid, Growing Base & Continued Execution % of Performance Enzyme’s $91M 2021 Revenue • Executing the Step-out Supply to Pfizer Sustainable o $21.3 million of revenue related to PAXLOVIDTM in 1Q’22 Manufacturing - Food o On-track to deliver $75-80 million in revenue in 202
Slide 5: Life Science Tools: High Growth
Life Science Tools: High Growth Strategic Investment and Partnership Opportunities: % of Performance Enzymes $91M 2021 Revenue Life Science Tools 8% Completed enzyme engineering with Molecular Assemblies to enable its Fully Enzymatic DNA Synthesis technology Sustainable MAI’s Key Customer Program se
Slide 6: Biotherapeutics: Rapid Pipeline Expansion & Validation
Biotherapeutics: Rapid Pipeline Expansion & Validation Preclinical Clinical # of Growing, Multi-Program Partnerships with World Leaders… Programs Discovery Research IND Enabling Phase I 2016 1 1 2018 4 1 1 …While Smartly Investing To Grow Our Asset Ownership Phase 1 Clinical Stage Assets: 2 1 1 • CD
Slide 7: Biotherapeutics: Pipeline Addressing Significant Unmet Patient Needs
Biotherapeutics: Pipeline Addressing Significant Unmet Patient Needs Program Discovery Preclinical Research IND-Enabling Phase 1 Partner CDX-6114 (Phenylketonuria) 1 CDX-7108 (Exocrine Pancreatic 2 Oral Enzyme Therapies Insufficiency) CDX-6512 (Homocystinuria) Wholly owned CDX-6210 (Maple Syrup Urin
Slide 8: Strong Q1 2022 Results
Strong Q1 2022 Results $35M $31M 72% Q1’22 Total Q1’22 Product Gross Product Margin Revenue +96% Revenue +200% vs. 59% in Q1’21 $33M $2M $94M Performance Novel Cash Available for Enzymes Biotherapeutics Growth. No Debt $20M $16M $8M R&D Expense SG&A Expense Net Loss 8
Slide 9: Q1'22 Segment Financials
Q1’22 Segment Financials Performance Enzymes Novel Biotherapeutics $33M $2M Q1’22 Revenue Q1’22 Revenue $15M ($11M) Q1’22 Income Q1’22 Loss from from Operations1 Operations1 Supported by $12M of corporate overhead expense (not allocated to either business segment) 1 Represents total revenues by segm
Slide 10: Reiterating 2022 Guidance
Reiterating 2022 Guidance $152-158M $112-118M 65-70% Total Revenue Product Revenue Product Gross Margin 10
Slide 11: Executing 2022 Corporate Goals and Catalysts
Executing 2022 Corporate Goals and Catalysts ❑ Continue driving widened adoption and product commercialization in pharma manufacturing Sustainable ❑ Deliver $75M+ enzyme sales to Pfizer for the manufacture of PAXLOVIDTM Manufacturing ❑ Step up new product offerings into larger, faster-to-commerciali
Slide 12: Nasdaq: CDXS www.codexis.com
Nasdaq: CDXS www.codexis.com